Hemab Therapeutics

Founded in 2019, Hemab Therapeutics is a cutting-edge biotech startup based in Denmark, with a focus on developing innovative treatments for rare bleeding and thrombotic disorders. The company boasts a robust pipeline of five different drug candidates, each targeting various bleeding or thrombotic disorders.

Investment rationale 

Hemab addresses rare bleeding and thrombotic disorders with few current treatment options, highlighting both a strong commercial potential and the opportunity to provide life-changing treatments for patients. Blood-related diseases are the therapeutic area with the highest likelihood of FDA approval. 

Headquarters: Copenhagen, Denmark

Website: https://hemab.com/

Responsible partner: Jannick Mortensen

Fund: MIM I